Literature DB >> 23178416

Life-threatening ACE inhibitor-induced angioedema after eleven years on lisinopril.

Johanna L Norman1, Whitney L Holmes, William A Bell, Shannon W Finks.   

Abstract

Angiotensin-converting enzyme inhibitors (ACE-Is) are the primary medication class implicated in drug-associated angioedema. Angioedema is most common early in ACE-I therapy, yet episodes can occur late in therapy and have been reported even as late as 10 years after single treatment initiation. We present a case of a 65-year-old African American woman who experienced 2 episodes of angioedema, with the second being life threatening after receiving several concomitant agents known to cause angioedema, most notably lisinopril for 11 years.

Entities:  

Keywords:  cardiology; emergency medicine; internal medicine

Mesh:

Substances:

Year:  2012        PMID: 23178416     DOI: 10.1177/0897190012465990

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  8 in total

1.  Life-threatening angio-oedema after the first dose of an ACE inhibitor-not an anaphylactic reaction.

Authors:  Troels Krogh Nielsen; Anette Bygum; Eva Rye Rasmussen
Journal:  BMJ Case Rep       Date:  2016-05-26

2.  ACE Inhibitor-Related Angioedema: Are Your Patients at Risk?

Authors:  Michele B Kaufman
Journal:  P T       Date:  2013-03

3.  Life-threatening ACE inhibitor-induced angio-oedema successfully treated with icatibant: a bradykinin receptor antagonist.

Authors:  Sarah Ostenfeld; Anette Bygum; Eva Rye Rasmussen
Journal:  BMJ Case Rep       Date:  2015-10-23

4.  Life threatening angioedema in a patient on ACE inhibitor (ACEI) confined to the upper airway.

Authors:  Abdulgafoor Muslim Tharayil; Arshad Hussain Chanda; Hakim Ahmad Shiekh; Mohamed Saad Elkhatib; Mohammed Nayeemuddin; Abdelhafiz Ali Ahmed Alshamandy
Journal:  Qatar Med J       Date:  2014-12-09

5.  Massive macroglossia, a rare side effect of COVID-19: clinical, histologic, and genomic findings in COVID-19-positive versus COVID-19-negative patients.

Authors:  Victoria A Mañón; David Chubb; Laura S Farach; Rachid Karam; Mary C Farach-Carson; Nadarajah Vigneswaran; Karan Saluja; Simon Young; Mark Wong; James C Melville
Journal:  Oral Maxillofac Surg       Date:  2022-01-03

6.  Lingual compression for acute macroglossia in a COVID-19 positive patient.

Authors:  Erickson Andrews; Jonathan Lezotte; Adam M Ackerman
Journal:  BMJ Case Rep       Date:  2020-07-16

7.  Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment.

Authors:  Eva Rye Rasmussen; Pär Hallberg; Ekaterina V Baranova; Niclas Eriksson; Malgorzata Karawajczyk; Caroline Johansson; Marco Cavalli; Cyrielle Maroteau; Abirami Veluchamy; Gunilla Islander; Svante Hugosson; Ingrid Terreehorst; Folkert W Asselbergs; Pia Norling; Hans-Erik Johansson; Hugo Kohnke; Ann-Christine Syvänen; Moneeza K Siddiqui; Chim C Lang; Patrik K E Magnusson; Qun-Ying Yue; Claes Wadelius; Christian von Buchwald; Anette Bygum; Ana Alfirevic; Anke H Maitland-van der Zee; Colin N A Palmer; Mia Wadelius
Journal:  Pharmacogenomics J       Date:  2020-02-21       Impact factor: 3.550

Review 8.  Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature.

Authors:  Teresa Brown; Jimmy Gonzalez; Catherine Monteleone
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-10-10       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.